Skip to Main Content



February 2024

Tigen Pharma Options MSK CAR T-cell therapy

November 2023

Sanders Tri-Institutional Therapeutics Discovery Institute, Inc. Celebrates New Name and 10 Years of Growth and Innovation

September 2023

NIH Center Grant Bolsters Male Contraceptive Research

February 2023

TDI's First Project Reaches Phase I Clinical Studies

February 2023

On-Demand Male Contraceptive Shows Promise in Preclinical Study

May 2022

Academia, Pharma Team up to Discover New Drugs in Fight Against SARS-CoV-2, Viruses of the Future

November 2020

Caribou Biosciences Licenses fully human anti-CD371 scFvs

March 2022

TDI collaboration leads to anti-ART1 antibody: A potential immune-enhancing cancer treatment

January 2022

Tri-I TDI Relocating to New RU Translational Center

January 2021

Dr Dan Heller Wins TDI Central Protein Database Prize

July 2020

Dr Sara Parsa Wins TDI Central Protein Database Prize

April 2020

TDI Launches Central Protein Database

March 2020

Bridge Medicines Licenses Product from RU Developed with TDI

February 2020

TDI Renews Ties with Takeda Pharmaceuticals and Bridge Medicines

March 2019

Small Molecule Discovered by TDI and Weill Cornell Medicine, Licensed to Bridge Medicine

October 2018

Ablexis, Inc. Licenses TDI-Generated Antibody

June 2018

Peter T. Meinke, PhD, Named New Sanders Director of the TDI

April 2018

TDI Renews Agreement with Schrödinger, Inc. for Access to Drug Discovery Software

March 2018

TDI Licenses First Project to Bridge Medicines

June 2017

TDI's Peter T. Meinke, PhD named "Hero of Chemistry"

May 2017

TDI teams with researchers at The Rockefeller University to develop novel dynein inhibitors

April 2017

Vincent Fischetti, PhD, TDI collaborator and professor at The Rockefeller University featured in Fierce Biotech

January 2017

Ablexis Announces Perpetual License of the AliaMab Mouse to the Tri-I TDI

September 2016

Discovering New Therapeutics through the Power of Philanthropy

June 2016

Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.

October 2015

Weill Cornell profiles the Tri-I TDI in the October issue of <em>Weill Cornell Medicine</em>

August 2015

Cyclofluidic Announces Drug Discovery Agreement with the Tri-I TDI

February 2015

Horizon Discovery Group Selected as Core Facility by the Tri-Institutional Therapeutics Discovery Institute

September 2014


December 2013

Accomplished Scientist and Entrepreneur Selected to Lead Tri-Institutional Therapeutics Discovery Institute

October 2013

Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

October 2013

Tripling Up for Early-Stage Drug Development

October 2013

Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda